Cupric Doping Hollow Prussian Blue Nanoplatform for Enhanced Cholesterol Depletion: a Promising Strategy for Breast Cancer Therapy and Metastasis Inhibition
Advanced Science · 2025
DOI: 10.1002/advs.202409967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Shuangqian Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, Biomedical Research Center of South China, College of Life …. Hauptthemen laut MEDLINE: Ferrocyanides, Breast Neoplasms, Cholesterol, Copper. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Fujian Province, Cultivation Plan for Science and Technology Innovation Team from the College of Life Sciences.
Abstract (Originalsprache)
The dysregulated cholesterol metabolism in breast cancer cells drives malignancy, invasion, and metastasis, emphasizing the significance of reducing abnormal cholesterol accumulation for effective cancer treatment and metastasis inhibition. Despite its promise, cholesterol oxidase (ChOx) encounters challenge due to limited catalytic efficiency and susceptibility to harsh conditions. To overcome these hurdles, biocompatible nanoplatforms (Cu‐HPB/C) tailored for efficient cholesterol depletion are introduced. Cu 2+ ‐doped hollow Prussian blue (Cu‐HPB) acts as a carrier, shelter, and enhancer for ChOx, bolstering tumor‐targeting ability, stability, and enzymatic activity. Tumor‐responsive released Cu 2+ notably augments ChOx activity, facilitating cholesterol depletion and disrupting lipid rafts, thereby impeding cell invasion and migration. Additionally, H 2 O 2 generated from the oxidase reaction enhances Cu‐HPB's chemo dynamic therapeutic efficacy. Transcriptomic analysis validates Cu‐HPB/C's impact on cholesterol homeostasis and reveals cell death mechanisms including oxidative stress, ferroptosis, cuproptosis, and apoptosis. Demonstrating therapeutic efficacy in both 4T1 tumor subcutaneous and metastasis mouse models, the study presents a direct and effective strategy for tumor therapy and metastasis inhibition through enhanced cholesterol depletion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, 1 Keji Road, Fuzhou, 350117, P. R.…
- The Straits Institute of Flexible Electronics (SIFE, Future Technologies), Straits Laboratory of Flexible Electronics (SLoFE) Fujian Normal University, Fuzhou, Fujian, 350117, P. R. China.
- Department of Gastroenterology, Fuzhou No. 1 Hospital Affiliated with Fujian Medical University, Fuzhou, Fujian, 350009, P. R. China.
ORCID-Profile: Xuemei Zeng
Förderung
- National Natural Science Foundation of China
- Science and Technology Planning Project of Fujian Province
- Cultivation Plan for Science and Technology Innovation Team from the College of Life Sciences
- Fujian Normal University
Zitieren
APA
Yan, S., Xue, P., Sun, Y., Bai, T., Shao, S., & Zeng, X. (2025). Cupric Doping Hollow Prussian Blue Nanoplatform for Enhanced Cholesterol Depletion: a Promising Strategy for Breast Cancer Therapy and Metastasis Inhibition. Advanced Science. https://doi.org/10.1002/advs.202409967
Vancouver
Yan S, Xue P, Sun Y, Bai T, Shao S, Zeng X. Cupric Doping Hollow Prussian Blue Nanoplatform for Enhanced Cholesterol Depletion: a Promising Strategy for Breast Cancer Therapy and Metastasis Inhibition. Advanced Science. 2025. doi:10.1002/advs.202409967
BibTeX
@article{Yan2025,
author = {Yan, Shuangqian and Xue, Panpan and Sun, Ying and Bai, Tingjie and Shao, Sijie and Zeng, Xuemei},
title = {Cupric Doping Hollow Prussian Blue Nanoplatform for Enhanced Cholesterol Depletion: a Promising Strategy for Breast Cancer Therapy and Metastasis Inhibition},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202409967}
}
EUVIMED